Targeting colon and kidney: Pathophysiological determinants of design strategy

Targeted Delivery of Small and Macromolecular Drugs

Volumn , Issue , 2010, Pages 351-370

  Narang, Ajit S ^a   Mahato, Ram I ^b  

^a BRISTOL MYERS SQUIBB   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84866737789     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1201/9781420087734     Document Type: Chapter

References (108)

1. Molema, G and Meijer, KF, Drug Targeting: Organ Specific Strategies (Wiley-VCH Verlag GmbH, Weinheim, Germany, 2001).
2. Faraji, AH and Wipf, P. Nanoparticles in cellular drug delivery. Bioorg. Med. Chem. 2009; 17(8): 2950-2962.
3. Raju, J, Srinivas, A, and Bairi, A. Drug targeting: Approaches to colonic drug delivery. J. Chem. Pharm. Sci. 2008; 1(2): 52-55.
4. Gershkovich, P, Wasan, KM, and Barta, CA. A review of the application of lipid-based systems in systemic, dermal/transdermal, and ocular drug delivery. Crit. Rev. Ther. Drug Carrier Syst. 2008; 25(6): 545-584.
5. Mayer, CR, Geis, NA, Katus, HA et al. Ultrasound targeted microbubble destruction for drug and gene delivery. Expert Opin. Drug Deliv. 2008; 5(10): 1121-1138.
6. Temming, K, Fretz, MM, and Kok, RJ. Organ- and cell-type specific delivery of kinase: A novel approach in the development of targeted drugs. Curr. Mol. Pharmacol. 2008; 1(1): 1-12.
7. Lim, CS. Organelle-specific targeting in drug delivery and design. Adv. Drug Deliv. Rev. 2007; 59(8):697.
8. Braun, K, Pipkorn, R, and Waldeck, W. Development and characterization of drug delivery systems for targeting mammalian cells and tissues: A review. Curr. Med. Chem. 2005; 12(16): 1841-1858.
9. Di Paolo, A. Liposomal anticancer therapy: Pharmacokinetic and clinical aspects. J. Chemother. 2004; 16(Suppl 4):90-93.
10. Zhang, Q-Y, Dunbar, D, Ostrowska, A et al. Characterization of human small intestinal cytochromes P-450. Drug Metab. Dispos. 1999; 27(7): 804-809.
11. Peters, WH, Kock, L, Nagengast, FM et al. Biotransformation enzymes in human intestine: Critical low levels in the colon? Gut 1991; 32(4):408-412.
12. Philip, AK, Dubey, RK, and Pathak, K. Optimizing delivery of flurbiprofen to the colon using a targeted prodrug approach. J. Pharm. Pharmacol. 2008; 60(5): 607-613.
13. Singh, BN. Modified-release solid formulations for colonic delivery. Recent Pat. Drug Deliv. Formul. 2007; 1: 53-63.
14. Gazzaniga, A, Maroni, A, Sangalli, ME et al. Time-controlled oral delivery systems for colon targeting. Expert Opin. Drug Deliv. 2006; 3(5): 583-597.
15. Hovgaard, L and Brondsted, H. Current applications of polysaccharides in colon targeting. Crit. Rev. Ther. Drug Carrier Syst. 1996; 13(3-4):185-223.
16. Ashford, M and Fell, JT. Targeting drugs to the colon: delivery systems for oral administration. J. Drug Target. 1994; 2(3): 241-257.
17. Chourasia, MK and Jain, SK. Pharmaceutical approaches to colon targeted drug delivery systems. J. Pharm. Pharm. Sci. 2003; 6(1): 33-66.
18. Chourasia, MK and Jain, SK. Polysaccharides for colon targeted drug delivery. Drug Deliv. 2004; 11(2): 129-148.
19. Kosaraju, SL. Colon targeted delivery systems: Review of polysaccharides for encapsulation and delivery. Crit. Rev. Food Sci. Nutr. 2005; 45(4): 251-258.
20. Kumar, P and Mishra, B. Colon targeted drug delivery systems-An overview. Curr. Drug Deliv. 2008; 5(3): 186-198.
21. Haupt, S and Rubinstein, A. The colon as a possible target for orally administered peptide and protein drugs. Crit. Rev. Ther. Drug Carrier Sys. 2002; 19(6): 499-551.
22. Jain, SK and Jain, A. Target-specific drug release to the colon. Expert Opin. Drug Deliv. 2008; 5(5): 483-498.
23. Guarner, F and Malagelada, JR. Gut flora in health and disease. Lancet 2003; 361 (9356):512-519.
24. Brown, JP, McGarraugh, GV, Parkinson, TM et al. A polymeric drug for treatment of inflammatory bowel disease. J. Med. Chem. 1983; 26(9): 1300-1307.
25. Kalala, W, Kinget, R, Van den Mooter, G et al. Colonic drug-targeting: In vitro release of ibuprofen from capsules coated with poly(ether-ester) azopolymers. Int. J. Pharm. 1996; 139(1,2):187-195.
26. Van den Mooter, G, Samyn, C, and Kinget, R. In vivo evaluation of a colon-specific drug delivery system:An absorption study of theophylline from capsules coated with azo polymers in rats. Pharm. Res. 1995; 12(2): 244-247.
27. Saffran, M, Kumar, GS, Neckers, DC et al. Biodegradable azopolymer coating for oral delivery of peptide drugs. Biochem. Soc. Trans. 1990; 18(5): 752-754.
28. Van den Mooter, G, Samyn, C, and Kinget, R. Azo polymers for colon-specific drug delivery. Int. J. Pharm. 1992; 87(1-3):37-46.
29. Vaidya, A, Jain, A, Khare, P et al. Metronidazole loaded pectin microspheres for colon targeting. J. Pharm. Sci. 2009; 98(11): 4229-4236.
30. Hodges, LA, Connolly, SM, Band, J et al. Scintigraphic evaluation of colon targeting pectin-HPMC tablets in healthy volunteers. Int. J Pharm. 2009; 370(1-2):144-150.
31. Freire, C, Podczeck, F, Veiga, F et al. Starch-based coatings for colon-specific delivery. Part II:Physicochemical properties and in vitro drug release from high amylose maize starch films. Eur. J. Pharm. Biopharm. 2009; 72(3): 587-594.
32. Calinescu, C and Mateescu, MA. Carboxymethyl high amylose starch: Chitosan self-stabilized matrix for probiotic colon delivery. Eur. J. Pharm. Biopharm. 2008; 70(2): 582-589.
33. Wilson, PJ and Basit, AW. Exploiting gastrointestinal bacteria to target drugs to the colon: An in vitro study using amylose coated tablets. Int. J. Pharm. 2005; 300(1-2):89-94.
34. Pitarresi, G, Tripodo, G, Calabrese, R et al. Hydrogels for potential colon drug release by thiol-ene conjugate addition of a new inulin derivative. Macromol. Biosci. 2008; 8(10): 891-902.
35. Maris, B, Verheyden, L, Van Reeth, K et al. Synthesis and characterisation of inulin-azo hydrogels designed for colon targeting. Int. J. Pharm. 2001; 213(1-2):143-152.
36. Ji, CM, Xu, HN, and Wu, W. Guar gum as potential film coating material for colon-specific delivery of fluorouracil. J. Biomater. Appl. 2009; 23(4): 311-329.
37. Ji, C, Xu, H, and Wu, W. In vitro evaluation and pharmacokinetics in dogs of guar gum and Eudragit FS30D-coated colon-targeted pellets of indomethacin. J. Drug Target. 2007; 15(2): 123-131.
38. Kelm, GR, Kondo, K, and Nakajima, A. Bisacodyl dosage form with multiple enteric polymer coatings for colonic delivery. Patent No. 5843479 (1998).
39. Makhlof, A, Tozuka, Y, and Takeuchi, H. pH-Sensitive nanospheres for colon-specific drug delivery in experimentally induced colitis rat model. Eur. J. Pharm. Biopharm. 2009; 72(1): 1-8.
40. Asghar, LF, Chure, CB, and Chandran, S. Colon specific delivery of indomethacin: effect of incorporating pH sensitive polymers in xanthan gum matrix bases. AAPS Pharm. Sci. Tech. 2009; 10(2): 418-429.
41. Zambito, Y, Baggiani, A, Carelli, V et al. Matrices for site-specific controlled-delivery of 5-fluorouracil to descending colon. J. Control. Release 2005; 102(3): 669-677.
42. Ashford, M, Fell, JT, Attwood, D et al. An in vivo investigation into the suitability of pH dependent polymers for colonic targeting. Int. J. Pharm. 1993; 95(1-3):193-199.
43. Wilson, CG and Washington, N. Assessment of disintegration and dissolution of dosage forms in vivo using gamma scintigraphy. Drug Dev. Ind. Pharm. 1988; 14(2-3):211-281.
44. Davis, SS, Hardy, JG, and Fara, JW. Transit of pharmaceutical dosage forms through the small intestine. Gut 1986; 27(8): 886-892.
45. Stevens, HNE. Pulsincap and hydrophilic sandwich (HS) capsules: Innovative time-delayed oral drug delivery technologies. Drugs Pharm. Sci. 2003; 126(Modified-Release Drug Delivery Technology):257-262.
46. Stevens, HNE, Wilson, CG, Welling, PG et al. Evaluation of pulsincap to provide regional delivery of dofetilide to the human GI tract. Int. J. Pharm. 2002; 236(1-2):27-34.
47. Fukui, E, Miyamura, N, Uemura, K et al. Preparation of enteric coated timed-release press-coated tablets and evaluation of their function by in vitro and in vivo tests for colon targeting. Int. J. Pharm. 2000; 204(1-2):7-15.
48. Hebden, JM, Wilson, CG, Spiller, RC et al. Regional differences in quinine absorption from the undisturbed human colon assessed using a timed release delivery system. Pharm. Res. 1999; 16(7): 1087-1092.
49. Liu, H, Yang, X-G, Nie, S-F et al. Chitosan-based controlled porosity osmotic pump for colon-specific delivery system: Screening of formulation variables and in vitro investigation. Int. J. Pharm. 2007; 332(1-2):115-124.
50. Hu, Z, Kimura, G, Mawatari, S et al. New preparation method of intestinal pressure-controlled colon delivery capsules by coating machine and evaluation in beagle dogs. J. Control. Release 1998; 56(1-3):293-302.
51. Hu, Z, Mawatari, S, Shimokawa, T et al. Colon delivery efficiencies of intestinal pressure-controlled colon delivery capsules prepared by a coating machine in human subjects. J. Pharm. Pharmacol. 2000; 52(10): 1187-1193.
52. Muraoka, M, Hu, Z, Shimokawa, T et al. Evaluation of intestinal pressure-controlled colon delivery capsule containing caffeine as a model drug in human volunteers. J. Control. Release 1998; 52(1-2):119-129.
53. Shibata, N, Ohno, T, Shimokawa, T et al. Application of pressure-controlled colon delivery capsule to oral administration of glycyrrhizin in dogs. J. Pharm. Pharmacol. 2001; 53(4): 441-447.
54. Mahkam, M and Doostie, L. The relation between swelling properties and cross-linking of hydrogels designed for colon-specific drug delivery. Drug Deliv. 2005; 12(6): 343-347.
55. Kakoulides, EP, Smart, JD, and Tsibouklis, J. Azocross-linked poly(acrylic acid) for colonic delivery and adhesion specificity: Synthesis and characterisation. J. Control. Release 1998; 52(3): 291-300.
56. Kakoulides, EP, Smart, JD, and Tsibouklis, J. Azocrosslinked poly(acrylic acid) for colonic delivery and adhesion specificity: In vitro degradation and preliminary ex vivo bioadhesion studies. J. Control. Release 1998; 54(1): 95-109.
57. Gao, SQ, Lu, ZR, Petri, B et al. Colon-specific 9-aminocamptothecin-HPMA copolymer conjugates containing a 1,6-elimination spacer. J. Control. Release 2006; 110(2): 323-331.
58. Gao, SQ, Lu, ZR, Kopeckova, P et al. Biodistribution and pharmacokinetics of colon-specific HPMA copolymer-9-aminocamptothecin conjugate in mice. J. Control. Release 2007; 117(2): 179-185.
59. Gao, SQ, Sun, Y, Kopeckova, P et al. Pharmacokinetic modeling of absorption behavior of 9-aminocamptothecin (9-AC) released from colon-specific HPMA copolymer-9-AC conjugate in rats. Pharm. Res. 2008; 25(1): 218-226.
60. Kaur, K and Kim, K. Studies of chitosan/organic acid/Eudragit RS/RL-coated system for colonic delivery. Int. J. Pharm. 2009; 366: 140-148.
61. Haas, M, Moolenaar, F, Meijer, DK et al. Specific drug delivery to the kidney. Cardiovasc. Drugs Ther. 2002; 16(6): 489-496.
62. Nangaku, M. Mechanisms of tubulointerstitial injury in the kidney: Final common pathways to end-stage renal failure. Intern. Med. 2004; 43(1): 9-17.
63. Kushibiki, T, Nagata-Nakajima, N, Sugai, M et al. Targeting of plasmid DNA to renal interstitial fibroblasts by cationized gelatin. Biol. Pharm. Bull. 2005; 28(10): 2007-2010.
64. Xia, Z, Abe, K, Furusu, A et al. Suppression of renal tubulointerstitial fibrosis by small interfering RNA targeting heat shock protein 47. Am. J. Nephrol. 2008; 28(1): 34-46.
65. Christensen, EI, Birn, H, Verroust, P et al. Membrane receptors for endocytosis in the renal proximal tubule. Int. Rev. Cytol. 1998; 180: 237-284.
66. Pacifici, GM, Viani, A, Franchi, M et al. Profile of drug-metabolizing enzymes in the cortex and medulla of the human kidney. Pharmacol. 1989; 39(5): 299-308.
67. Tuffin, G, Waelti, E, Huwyler, J et al. Immunoliposome targeting to mesangial cells: A promising strategy for specific drug delivery to the kidney. J. Am. Soc. Nephrol. 2005; 16(11): 3295-3305.
68. Tuffin, G, Huwyler, J, Waelti, E et al. Drug targeting using OX7-immunoliposomes: correlation between Thy1.1 antigen expression and tissue distribution in the rat. J. Drug Target. 2008; 16(2): 156-166.
69. Asgeirsdottir, SA, Kamps, JA, Bakker, HI et al. Site-specific inhibition of glomerulonephritis progression by targeted delivery of dexamethasone to glomerular endothelium. Mol. Pharm. 2007; 72(1): 121-131.
70. Chadban, SJ and Atkins, RC. Glomerulonephritis. Lancet 2005; 365(9473): 1797-1806.
71. Tam, FW. Current pharmacotherapy for the treatment of crescentic glomerulonephritis. Expert Opin. Investig. Drugs 2006; 15(11): 1353-1369.
72. Manil, L, Davin, JC, Duchenne, C et al. Uptake of nanoparticles by rat glomerular mesangial cells in vivo and in vitro. Pharm. Res. 1994; 11(8): 1160-1165.
73. Guzman, M, Aberturas, MR, Rodriguez-Puyol, M et al. Effect of nanoparticles on digitoxin uptake and pharmacologic activity in rat glomerular mesangial cell cultures. Drug Deliv. 2000; 7(4): 215-222.
74. Stella, VJ. Prodrugs as therapeutics. Expert Opin. Ther. Pat. 2004; 14(3): 277-280.
75. Jung, D and Dorr, A. Single-dose pharmacokinetics of valganciclovir in HIV- and CMV-seropositive subjects. J. Clin. Pharm. 1999; 39(8): 800-804.
76. Weller, S, Blum, MR, Doucette, M et al. Pharmacokinetics of the acyclovir pro-drug valaciclovir after escalating single- and multiple-dose administration to normal volunteers. Clin. Pharm. Ther. 1993; 54(6): 595-605.
77. Amidon, GL and Walgreen, CR, Jr. 5′-Amino acid esters of antiviral nucleosides, acyclovir, and AZT are absorbed by the intestinal PEPT1 peptide transporter, Pharm. Res. 1999; 16(2):175.
78. Borner, V, Fei, YJ, Hartrodt, B et al. Transport of amino acid aryl amides by the intestinal H+/peptide cotransport system, PEPT1. Eur. J Biochem./FEBS 1998; 255(3): 698-702.
79. Han, H, de Vrueh, RL, Rhie, JK et al. 5′-Amino acid esters of antiviral nucleosides, acyclovir, and AZT are absorbed by the intestinal PEPT1 peptide transporter. Pharm. Res. 1998; 15(8): 1154-1159.
80. Umapathy, NS, Ganapathy, V, and Ganapathy, ME. Transport of amino acid esters and the aminoacid- based prodrug valganciclovir by the amino acid transporter ATB(0,+). Pharm. Res. 2004; 21(7): 1303-1310.
81. Sakaeda, T, Siahaan, TJ, Audus, KL et al. Enhancement of transport of d-melphalan analogue by conjugation with l-glutamate across bovine brain microvessel endothelial cell monolayers. J. Drug Target. 2000; 8(3): 195-204.
82. Cummings, J, Matheson, LM, Maurice, L et al. Pharmacokinetics, bioavailability, metabolism, tissue distribution and urinary excretion of gamma-l-glutamyl-l-dopa in the rat. J. Pharm. Pharmacol. 1990; 42(4): 242-246.
83. Boateng, YA, Barber, HE, MacDonald, TM et al. Disposition of gamma-glutamyl levodopa (gludopa) after intravenous bolus injection in healthy volunteers. Br. J. Clin. Pharmacol. 1991; 31(4): 419-422.
84. Lee, MR. Five years’ experience with gamma-l-glutamyl-l-dopa: a relatively renally specific dopaminergic prodrug in man. J. Auton. Pharmacol. 1990; 10(Suppl 1): s103-108.
85. Murakami, T, Kohno, K, Yumoto, R et al. N-acetyl-l-gamma-glutamyl derivatives of p-nitroaniline, sulphamethoxazole and sulphamethizole for kidney-specific drug delivery in rats. J. Pharm. Pharmacol. 1998; 50(5): 459-465.
86. Orlowski, M, Mizoguchi, H, and Wilk, S. N-acyl-gamma-glutamyl derivatives of sulfamethoxazole as models of kidney-selective prodrugs. J. Pharmacol. Exp. Ther. 1980; 212(1): 167-172.
87. Drieman, JC, Thijssen, HH, and Struyker-Boudier, HA. Renal selective N-acetyl-gamma-glutamyl prodrugs. II. Carrier-mediated transport and intracellular conversion as determinants in the renal selectivity of N-acetyl-gamma-glutamyl sulfamethoxazole. J. Pharmacol. Exp. Ther. 1990; 252(3): 1255-1260.
88. Drieman, JC, Thijssen, HH, Zeegers, HH et al. Renal selective N-acetyl-gamma-glutamyl prodrugs: A study on the mechanism of activation of the renal vasodilator prodrug CGP 22979. Br. J. Pharmacol. 1990; 99(1): 15-20.
89. Hashida, M, Akamatsu, K, Nishikawa, M et al. Design of polymeric prodrugs of prostaglandin E(1) having galactose residue for hepatocyte targeting. J. Control. Release 1999; 62(1-2):253-262.
90. Akamatsu, K, Yamasaki, Y, Nishikawa, M et al. Synthesis and pharmacological activity of a novel watersoluble hepatocyte-specific polymeric prodrug of prostaglandin E(1) using lactosylated poly(l-glutamic hydrazide) as a carrier. Biochem. Pharmacol. 2001; 62(11): 1531-1536.
91. Choi, HS, Liu, W, Misra, P et al. Renal clearance of quantum dots. Nat. Biotechnol. 2007; 25(10): 1165-1170.
92. Haas, M, de Zeeuw, D, van Zanten, A et al. Quantification of renal low-molecular-weight protein handling in the intact rat. Kidney Int. 1993; 43(4): 949-954.
93. Franssen, EJ, Koiter, J, Kuipers, CA et al. Low molecular weight proteins as carriers for renal drug targeting. Preparation of drug-protein conjugates and drug-spacer derivatives and their catabolism in renal cortex homogenates and lysosomal lysates. J. Med. Chem. 1992; 35(7): 1246-1259.
94. Christensen, EI and Verroust, PJ. Megalin and cubilin, role in proximal tubule function and during development. Pediat. Nephrol. 2002; 17(12): 993-999.
95. Haas, M, Kluppel, ACA, Wartna, ES et al. Drug-targeting to the kidney: Renal delivery and degradation of a naproxen-lysozyme conjugate in vivo. Kidney Int. 1997; 52(6): 1693-1699.
96. Franssen, EJF, Moolenaar, F, de Zeeuw, D et al. Low-molecular-weight proteins as carriers for renal drug targeting: Naproxen coupled to lysozyme via the spacer l-lactic acid. Pharm. Res. 1993; 10(7): 963-969.
97. Windt, WAKM, Prakash, J, Kok, RJ et al. Renal targeting of captopril using captopril-lysozyme conjugate enhances its antiproteinuric effect in adriamycin-induced nephrosis. JRAAS 2004; 5(4): 197-202.
98. Prakash, J, van Loenen-Weemaes, AM, Haas, M et al. Renal-selective delivery and angiotensin-converting enzyme inhibition by subcutaneously administered captopril-lysozyme. Drug Metab. Dispos. 2005; 33(5): 683-688.
99. Kok, RJ, Grijpstra, F, Walthuis, RB et al. Specific delivery of captopril to the kidney with the prodrug captopril-lysozyme. J. Pharm. Exp. Ther. 1999; 288(1): 281-285.
100. Zhang, Z, Zheng, Q, Han, J et al. The targeting of 14-succinate triptolide-lysozyme conjugate to proximal renal tubular epithelial cells. Biomaterials 2009; 30(7): 1372-1381.
101. Watanabe, A, Nagai, J, Adachi, Y et al. Targeted prevention of renal accumulation and toxicity of gentamicin by aminoglycoside binding receptor antagonists. J. Control. Release 2004; 95(3): 423-433.
102. Inoue, M, Nishikawa, M, Sato, E et al. Synthesis of superoxide dismutase derivative that specifically accumulates in renal proximal tubule cells. Archiv. Biochem. Biophys. 1999; 368(2): 354-360.
103. Kamada, H, Tsutsumi, Y, Sato-Kamada, K et al. Synthesis of a poly(vinylpyrrolidone-co-dimethyl maleic anhydride) co-polymer and its application for renal drug targeting. Nat. Biotechnol. 2003; 21(4): 399-404.
104. Kodaira, H, Tsutsumi, Y, Yoshioka, Y et al. The targeting of anionized polyvinylpyrrolidone to the renal system. Biomaterials 2004; 25(18): 4309-4315.
105. Kissel, M, Peschke, P, Subr, V et al. Detection and cellular localisation of the synthetic soluble macromolecular drug carrier pHPMA. Eur. J. Nucl. Med. Mol. Imaging 2002; 29(8): 1055-1062.
106. Yuan, ZX, Sun, X, Gong, T et al. Randomly 50% N-acetylated low molecular weight chitosan as a novel renal targeting carrier. J. Drug Target. 2007; 15(4): 269-278.
107. Wigler, N, O’Brien, M, and Rosso, R. Reduced cardiac toxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin (Caelyx®/Doxil®) vs. doxorubicin for first-line treatment of metastatic breast cancer. In Conference Proceeding, American Society of Clinical Oncology, 2002, Orlando, FL.
108. Dolman, ME, Fretz, MM, Segers, GJ et al. Renal targeting of kinase inhibitors. Int. J. Pharm. 2008; 364(2): 249-257.